Research analysts who have asked questions during BillionToOne earnings calls.
AB
Andrew Brackman
William Blair
2 questions for BLLN
Also covers: DGX, LH, VCYT
BC
Brandon Couillard
Wells Fargo
2 questions for BLLN
Also covers: RVTY, TECH
CW
Casey Woodring
JPMorgan Chase & Co.
2 questions for BLLN
Also covers: A, CRL, HOLX +12 more
David Westenberg
Piper Sandler
2 questions for BLLN
Also covers: ADPT, AKYA, CTKB +13 more
Mark Massaro
BTIG, LLC
2 questions for BLLN
Also covers: ADPT, AKYA, BNGO +19 more
Tycho Peterson
Jefferies
2 questions for BLLN
Also covers: A, AVTR, BIO +22 more
Recent press releases and 8-K filings for BLLN.
BillionToOne Updates Revenue Guidance and Highlights GAAP Profitability at J.P. Morgan Healthcare Conference
BLLN
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- BillionToOne reported strong financial performance, achieving an annualized revenue run rate of $334 million as of Q3 and $153 million in GAAP revenues for 2024.
- The company updated its revenue guidance, projecting $293-$299 million for 2025 and $415-$430 million for 2026, significantly exceeding previous projections.
- BillionToOne achieved GAAP profitability and positive cash flows as of Q3, with 70% gross margins, and anticipates being GAAP operating margin positive for full years 2025 and 2026.
- Growth is fueled by a 51% year-over-year increase in test volume, an average selling price (ASP) of over $500 per test, and expanded network coverage reaching over 250 million contracted lives.
- Strategic initiatives include expanding into the oncology MRD market, a $30 billion opportunity, and investing in Epic Systems integration to drive health system growth.
Jan 12, 2026, 5:45 PM
BillionToOne Updates Revenue Guidance and Highlights Strong Financial Performance at J.P. Morgan Healthcare Conference
BLLN
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- BillionToOne reported rapid revenue growth, achieving a $334 million annualized revenue run rate as of the end of Q3 in five years and reaching GAAP profitability and positive cash flows as of Q3. The company projects to be GAAP operating margin positive for full year 2025 and 2026.
- The company provided updated revenue guidance, projecting $293 million-$299 million for 2025 (up from a previous projection of $220 million) and $415 million-$430 million for 2026 (up from $330 million).
- BillionToOne maintains a 70% gross margin and is the second largest prenatal lab. Its Northstar Select oncology test demonstrated superior performance, detecting 51% more SNVs and 109% more CNVs than competitors in a head-to-head study, and the company plans to expand into the MRD market in 2026, a $30 billion potential opportunity.
Jan 12, 2026, 5:45 PM
BillionToOne Presents Strong Financial Performance and Growth Projections at JPM Healthcare Conference 2026
BLLN
Earnings
Guidance Update
Revenue Acceleration/Inflection
- BillionToOne reported strong financial performance, with actual revenue of $153M in 2024 and current projections for 2025 revenue between $293M and $299M, and $415M to $430M for 2026.
- The company achieved profitability with an operating income of +$6M year-to-date for Q3 2025, a significant improvement from a -$47M operating loss in 2024.
- Gross margin has rapidly expanded, reaching 70% in Q3 2025, up from 53% in Q3 2024.
- Total test volume is rapidly increasing with 51% year-over-year growth, reaching 163K tests in 2025, driven by its UNITY prenatal and NORTHSTAR cancer care platforms.
Jan 12, 2026, 5:45 PM
BillionToOne Updates Revenue Guidance and Highlights Strong Growth
BLLN
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- BillionToOne reported an annualized revenue run rate of $334 million as of the end of Q3 , achieving 70% gross margins and GAAP profitability and positive cash flows as of Q3.
- The company updated its revenue guidance for 2025 to $293-$299 million and for 2026 to $415-$430 million, expecting to be GAAP operating margin positive for both full years.
- BillionToOne is the second largest prenatal lab and is expanding in the oncology market with Northstar Select and Response, addressing a $20 billion U.S. market.
- Test volume grew 51% year over year , and the company plans to expand into the MRD market this year, representing a $30 billion potential opportunity.
Jan 12, 2026, 5:45 PM
BillionToOne Initiates 2026 Guidance
BLLN
Guidance Update
Revenue Acceleration/Inflection
- BillionToOne, Inc. (BLLN) initiated its full year 2026 guidance on January 12, 2026, projecting total revenue of $415 million to $430 million.
- This 2026 revenue guidance signifies a growth of 40% to 45% compared to the midpoint of the full year 2025 guidance range.
- The company also anticipates achieving positive GAAP operating income for the full year 2026.
Jan 12, 2026, 1:09 PM
BillionToOne Announces Strong Q3 2025 Results and Full-Year Guidance
BLLN
Earnings
Guidance Update
Revenue Acceleration/Inflection
- BillionToOne reported strong Q3 2025 financial results, with total revenue reaching $83.5 million, a 117% increase year-over-year, and an annualized revenue run rate (ARR) of $334 million.
- The company achieved 70% gross margins and its first quarter of positive GAAP operating income of $9.6 million, or 11.5% operating margin, in Q3 2025. Net income was $1.5 million, or $0.10 per diluted share.
- Test accession volume grew 51% year-over-year to 163,000 tests in Q3 2025, with oncology revenue growing 664% year-over-year to $8.7 million.
- BillionToOne issued full-year 2025 revenue guidance of $293 million to $299 million, representing 92% to 96% growth compared to 2024, and anticipates positive GAAP operating income for both Q4 and the full year 2025.
- The company completed its initial public offering in November, raising $314 million in gross proceeds, and plans strategic investments, including Epic EMR integration, to further drive growth.
Dec 9, 2025, 9:30 PM
BillionToOne Reports Strong Q3 2025 Results with Significant Revenue and Profitability Growth
BLLN
Earnings
Guidance Update
Revenue Acceleration/Inflection
- BillionToOne reported Q3 2025 revenue of $83.5 million, marking 117% year-over-year growth, and achieved an annualized revenue run-rate (ARR) of $334 million.
- The company demonstrated strong profitability with a 70% gross margin in Q3 2025, a 17 percentage point expansion from Q3 2024, and an 11.5% GAAP operating margin, making all year-to-date GAAP profitability metrics positive.
- Test volumes increased 51% year-over-year to 162,900 in Q3 2025, with the average sales price (ASP) growing 44% year-over-year to $501 per test.
- BillionToOne raised $314 million in gross proceeds from its IPO and provided Q4 2025 revenue guidance of $84-90 million and full-year 2025 revenue guidance of $293-299 million.
Dec 9, 2025, 9:30 PM
BillionToOne Reports Strong Q3 2025 Results and Provides 2025 Guidance
BLLN
Earnings
Guidance Update
New Projects/Investments
- BillionToOne reported strong financial results for Q3 2025, with total revenue of $83.5 million, a 117% increase year-over-year, and achieved its first quarter of positive GAAP operating income of $9.6 million. The company also reported a gross margin of 70%, a 17 percentage point expansion from Q3 2024.
- The company completed a successful initial public offering (IPO) in November, raising $314 million in gross proceeds. As of the end of Q3, BillionToOne had $195 million in cash and equivalents, which increased to $286.4 million in net proceeds after the IPO.
- BillionToOne provided full-year 2025 revenue guidance of $293 million to $299 million, representing 92% to 96% growth over 2024, and expects Q4 2025 revenue between $84 million and $90 million. The company anticipates positive GAAP operating income for both Q4 and the full year 2025.
- Strategic developments include signing a contract with Epic for Aura implementation to accelerate UnityToOne adoption in health systems , and an exclusive agreement with Johnson & Johnson for the UnityToOne fetal antigen test as a companion diagnostic for HDFN. The company aims for Medicare coverage for Northstar Response before the end of 2026, with a planned launch of a tumor-naive MRD test towards the end of 2026.
Dec 9, 2025, 9:30 PM
BillionToOne Reports Strong Q3 2025 Results and Provides Full Year Guidance
BLLN
Earnings
Guidance Update
New Projects/Investments
- BillionToOne reported Q3 2025 total revenue of $83.5 million, marking a 117% increase year-over-year, and achieved a gross margin of 70%. The company recorded its first quarter of positive GAAP operating income of $9.6 million and net income of $1.5 million, or $0.10 per diluted share.
- The company completed a successful initial public offering (IPO) in November, raising $314 million in gross proceeds.
- For the full year 2025, BillionToOne expects total revenue between $293 million and $299 million, representing 92%-96% growth compared to 2024, with Q4 revenue expectations of $84 million to $90 million. The company anticipates positive GAAP operating income for both Q4 and the full year 2025.
- Strategic initiatives include signing a contract with Epic for Aura implementation to accelerate UnityToOne adoption in health systems and expecting Medicare coverage for Northstar Select Response before the end of 2026.
Dec 9, 2025, 9:30 PM
BillionToOne Reports Q3 2025 Results and Appoints New Board Member
BLLN
Earnings
Guidance Update
Board Change
- BillionToOne reported total revenue of $83.5 million in the third quarter of 2025, marking a 117% increase compared to the third quarter of 2024.
- The company achieved an operating income of $9.6 million in Q3 2025, a significant improvement from an operating loss of ($12.6) million in Q3 2024, and a net income of $1.5 million available to common shareholders, or $0.10 per diluted share.
- BillionToOne provided guidance for full year 2025 revenue between $293 million and $299 million and Q4 2025 revenue between $84 million and $90 million, anticipating positive operating income for both periods.
- Anthony Pagano has been appointed to the Board of Directors and will serve as Chair of the Audit Committee, effective January 1, 2026.
Dec 9, 2025, 9:15 PM
Quarterly earnings call transcripts for BillionToOne.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more